u/JRshoe1997

ABT trades at a 16x EV/EBITDA multiple, its cheapest in years, while being a "Dividend King" with a healthy balance sheet and dominant, recession-resistant segments (Medical Devices, Pharmaceuticals). The market is overly punishing the stock for short-term issues (consumer pushback in Nutrition, post-pandemic Diagnostics decline), creating a valuation gap for a stable, growing company. ABT is a high-quality stock that is a buy for long-term value and dividend growth investors. Ongoing baby formula lawsuits harming the Nutrition segment, and the large acquisition/ integration of Exact Sciences failing to stabilize the Diagnostics segment.